Wescadia Group’s BioDeal 360™: Analysis of Deal Activity in the Australian Life Science Sector

Wescadia Group, a healthcare consultancy firm, announces the release of its report “BioDeal 360™". The report provides strategic analysis, commentary, insight, and opinion on selected deals in the Australian life science industry in 2012.
 
 
Spread the Word
Listed Under

Tags:
* Pharmaceutical
* Biotechnology
* Healthcare
* Industry
* Life Science

Industrys:
* Biotech
* Health

Location:
* Kent Town - South Australia - Australia

Subject:
* Products

Dec. 17, 2012 - PRLog -- Wescadia Group, a healthcare consultancy firm, announces the release of its report “BioDeal 360™". The purpose of the report is to provide an overview of selected deals such as in-licensing, out-licensing or mergers and acquisitions (M&A) by Australian life science companies over the last 12 months and to understand the strategic significance of the deals.

“Our profiles of the deals entered into by Australian life science companies shows that their innovative technologies have a pivotal role in meeting the strategic needs of their partners,” said Marcus Bain, Ph.D., managing director of Wescadia Group.

Questions Answered:
•   Which pharmaceutical, biotechnology, medical device and diagnostic players in Australia have been active in deals? What are the reasons for the different level of deal activity between the different players?
•   What is the rationale for transactions between Australian life science companies and their partners? What approaches maximize the value of transactions between Australian life science companies and their partners?
•   How can Australian life science companies capitalize on the challenges facing big pharma?

Companies Mentioned:
AstraZeneca
Bionomics
Cochlear
CSL
Eclipse Therapeutics
Geron Corporation
Immuron
Ironwood Pharmaceuticals
Marinova
Neuron Systems
Optimer Pharmaceuticals
Paladin Laboratories
pSivida
ResMed
Siemens
Sienna Cancer Diagnostics
Specialised Therapeutics Australia
Starpharma
Stemtech International
Umbian
Universal Biosensors

For more information on the report or to order a copy, please visit us at http://wescadiagroup.com/free-resources/biodeal-360/.

About Wescadia Group
Wescadia Group is a healthcare consultancy firm that works with life science organizations to help them achieve sustainable growth, bring innovative treatments to market and maximize the value of their assets.    

Contact:
Wescadia Group Pty Ltd (ABN 26.156.459.504)
Marcus Bain
Phone: +61. 8.8125.5820
Email: marcus.bain@wescadiagroup.com
Facebook: http://www.facebook.com/pages/Wescadia-Group-Pty-Ltd/2824...
Linkedin: http://www.linkedin.com/company/2649650
Twitter: https://twitter.com/wescadiagroup
End
Source:
Email:***@wescadiagroup.com Email Verified
Phone:+61 8 8125 5820
Zip:5071
Tags:Pharmaceutical, Biotechnology, Healthcare, Industry, Life Science
Industry:Biotech, Health
Location:Kent Town - South Australia - Australia
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Wescadia Group Pty Ltd News
Trending
Daily News
Weekly News



Like PRLog?
9K2K1K
Click to Share